Pharmaceuticals News and Research

RSS

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.

2 Dec 2011

ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis

ADVENTRX Pharmaceuticals, Inc. announced today that it met with the U.S. Food and Drug Administration (FDA) to review development plans for ANX-188 (purified poloxamer 188), the Company's first-in-class treatment for sickle cell patients experiencing vaso-occlusive crisis.

1 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patient has been dosed in its open-label phase IIa trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of idiopathic adhesive capsulitis of the shoulder, also known as Frozen Shoulder syndrome.

1 Dec 2011

First Edition: December 1, 2011

In today's headlines, Republicans in Congress advance plan to charge wealthy beneficiaries more for Medicare in order to cover the costs of the proposaed payroll tax extension.

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

New issue of Index on Censorship magazine calls for debate into science and transparency

As thousands more emails from the University of East Anglia's Climatic Research Unit (CRU) are leaked on the internet, the latest issue of Index on Censorship magazine, 'Dark Matter', calls for a debate into science and transparency.

1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Medical websites provide harmful information about postherpetic neuralgia treatments

Health information is plentiful on the Internet and many Web surfers consider medical advice they find online to be a cheaper alternative to visiting a doctor, according to some studies. However, the risk of obtaining useless or even harmful medical information from some websites is high for patients with postherpetic neuralgia, a common complication of shingles, according to new research reported in The Journal of Pain, published by the American Pain Society.

1 Dec 2011

Santaris Pharma wins two LNA patent re-examination cases in the U.S.

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals.

1 Dec 2011

Harvard SEAS, BASF to co-host symposium on pharmaceutical nanoformulations

From targeted cancer chemotherapy to the guarantee of successful organ transplants, the 21st century may prove to be the age of big ideas in medicine. The drugs themselves, though, will be miniscule. Experts in chemistry, applied physics, materials science, and pharmaceutical science are gathering this week for the BASF Advanced Research Initiative at Harvard University's symposium on pharmaceutical nanoformulations.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Ranbaxy receives FDA approval to manufacture and market generic Lipitor

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.

1 Dec 2011

Ranbaxy and Teva announce generic Lipitor agreement

Teva Pharmaceutical Industries Ltd. announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited, a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva.

1 Dec 2011

Watson commences shipping of generic LIPITOR

Watson Pharmaceuticals, Inc. today confirmed that Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR (atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc.

30 Nov 2011

Pfizer backs its highest grosser Lipitor

Pfizer’s Lipitor, a blood cholesterol lowering drug, is a popular one the among general population. However now that a generic competition for the drug has arrived in the market the company has devised discounts and incentives for patients, insurers and companies that process prescriptions that will, at least for the next six months, make the brand name drug about as cheap as or cheaper than the generics.

30 Nov 2011

State roundup: No Mass. insurance mandate referendum

If you chafe against the Massachusetts requirement that you have health insurance, sorry but you won't have a chance to vote against it - not in the next election, anyway. Backers of a ballot measure to repeal the state's insurance mandate sent out an email last week saying they had failed to gather the needed signatures.

30 Nov 2011

Groups push for legislation to encourage Medicaid programs to use generic drugs

A group of pharmacists, generic drug makers and consumer interest organizations are trying to build support for a bill that offers states financial incentives to use generic drugs under Medicaid instead of brand-name drugs, which supporters say will save both states and the federal government money.

30 Nov 2011

Associated Press examines Chinese vaccine makers' entry into international market

"China's vaccine makers are gearing up over the next few years to push exports in a move that should lower costs of lifesaving immunizations for the world's poor and provide major new competition for the big Western pharmaceutical companies," the Associated Press reports in a feature examining the entry of Chinese vaccine makers into the international market.

30 Nov 2011

BioMarin commences GALNS Phase 2 study in mucopolysaccharidosis IVA

BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA.

30 Nov 2011